HighTower Advisors’s Structure Therapeutics GPCR Stock Holding History
Bought
Maintained
Sold
Other funds holding GPCR
BBA
HighTower Advisors's GPCR Position: Q3 2026 in Review
HighTower Advisors reduced its Structure Therapeutics (GPCR) stake by 1.6% in Q3 2026, selling an estimated $7.7K and leaving 9,865 shares worth $308K. The position accounts for ﹤0.01% of the portfolio, ranked #3193.
HighTower Advisors first reported a position in GPCR in Q3 2025 and has held it in 5 quarters since. The position peaked at $648K in Q4 2025. 169 funds tracked by Wall St. Rank hold GPCR as of Q3 2026.
- HighTower Advisors held 9,865 shares of Structure Therapeutics worth $308K as of Q3 2026.
- HighTower Advisors sold 164 Structure Therapeutics shares in Q3 2026, an estimated $7.7K.
- Structure Therapeutics made up ﹤0.01% of HighTower Advisors's portfolio in Q3 2026, its #3193 holding.
- HighTower Advisors first reported a position in Structure Therapeutics in Q3 2025 and has held it in 5 quarters since.
- HighTower Advisors's Structure Therapeutics position peaked at $648K in Q4 2025.
- 169 funds tracked by Wall St. Rank held Structure Therapeutics as of Q3 2026.
Based on HighTower Advisors's 13F filing for Q3 2026, filed 10 Nov 2026.